Benzinga19 Ağustos 2026 08:30 TR16 gün önce

BMO Capital Initiates Coverage On Alnylam Pharmaceuticals with Outperform Rating, Announces Price Target of $318

BMO Capital analyst David Lebowitz initiates coverage on Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform rating and announces Price Target of $318.

Haberin Tamamı Kaynağında

Burada gördüğün özet, haber sağlayıcısından geliyor; metnin devamı yayıncının sitesinde — Benzinga

Kaynakta Oku

Haberde Geçen Şirketler

ALNYAlnylam Pharmaceuticals Inc265,60+ %0,42

Benzer Haberler

Sodexo : Monthly disclosure on share capital and voting rights August 31, 2026
Yahoo1 saat önce
ANF vs. TPR: Which Stock Is the Better Value Option?
Yahoo1 saat önce
Anthropic's IPO Push Just Got a $15 Billion Backstop
Yahoo1 saat önce
Why Is Circle Internet Group, Inc. (CRCL) Up 63.1% Since Last Earnings Report?
Yahoo1 saat önce
Radian (RDN) Up 1.5% Since Last Earnings Report: Can It Continue?
Yahoo1 saat önce